STING1 and neoplasm: PancVAX is a vaccine composed of synthetic peptides and a STING agonist-based adjuvant, ADU-V19, which when used in combination with an OX40 agonist and anti-PD-1 therapy in preclinical models leads to significant tumor regression and improved survival [122].